BSP invented a novel, non-invasive and highly reliable solutions for the diagnosis and monitoring of Ischemic Heart Disease. HyperQ technology detects ECG stress induced ischemia and acute ischemia in resting ECG tests.

Statistically over 50% of the patients are asymptomatic and become aware of the heart disease condition through an adverse event. HyperQ provides superior sensitivity and accurate results. It analyses the high-frequency QRS Depolarization segment of the cardiac cycle. Conventional ECG analysis of the ST segment is related to the Repolarization. HyperQ prevents unnecessary exposure to radioactive or invasive procedures associated with advanced Ischemic Heart Disease (IHD) diagnosis systems. HyperQ sensitivity and specificity are similar to those of radioactive procedures, performing equally well in men and women, thus allowing for a dramatically enhanced diagnosis in women, saving the time and cost of other further, expensive IHD tests. To date, thousands of patients were diagnosed by the HyperQ in controlled clinical studies, in hospitals and private physician offices.

The clinical results are published in leading cardiology journals.
HyperQ is a proprietary and patented technology. The American Heart Association (AHA) included HyperQ in its last statement on exercise standards for testing (published in August 2013), pointing out that it has been found to have useful test performance for detection of CAD. The HyperQ received FDA clearance and CE marking.

To learn more about the company please visit their website: www.bsp.co.il

BSP Medical will be visiting New Delhi and Jaipur end of this month as part of the Medical Delegation coming from Israel to India.

In Jaipur

Date: July 31st July 2018

Time: 13:00-17:00

Event: B2B Interaction (with Indian hospitals, Companies and distributors)

In New Delhi

Date: August 2nd 2018

Time: 10:30-14:00

Event: B2B Interaction (with Indian hospitals, Companies and distributors)

In order to meet them or know more about the activity please contact:

Mr. Tejinder Singh, Senior Trade Officer, New Delhi – tejinder.singh@israeltrade.gov.il